SLC19A3, CRP, and FGF8 have been reported to have clinical prognostic value in CC progression [34]; our study is the first to characterize SLC19A3 as a prognostic signature through NAD+ metabolism. This evidence concerns the gene SLC19A3 and cholangiocarcinoma.